Cellivery Therapeutics Inc
KOSDAQ:268600
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cellivery Therapeutics Inc
Cash
Cellivery Therapeutics Inc
Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Cellivery Therapeutics Inc
KOSDAQ:268600
|
Cash
₩133.8m
|
CAGR 3-Years
480%
|
CAGR 5-Years
166%
|
CAGR 10-Years
N/A
|
|
|
Samsung Biologics Co Ltd
KRX:207940
|
Cash
₩3.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
ADM Korea Inc
KOSDAQ:187660
|
Cash
₩2.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
P
|
Peptron Inc
KOSDAQ:087010
|
Cash
₩3.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-3%
|
|
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Cash
₩30.5B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Cash
₩795k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-83%
|
CAGR 10-Years
-46%
|
|
Cellivery Therapeutics Inc
Glance View
Cellivery Therapeutics, Inc. engages in the research and development of medicine and pharmacy. The company is headquartered in Seoul, Seoul. The company went IPO on 2018-11-09. The firm develops biotherapeutics capable of entering cells in vivo through proprietary therapeuticmolecule systemic delivery technology (TSDT). The firm research and develop therapeutic drug candidates such as Parkinson’s disease treatment, pancreatic cancer and solid cancer treatment, bone formation promoter, as well as advanced obesity & type II diabetes mellitus; new drugs for research including DNA recombinase and reprogramming factors (RFs).
See Also
What is Cellivery Therapeutics Inc's Cash?
Cash
133.8m
KRW
Based on the financial report for Sep 30, 2024, Cellivery Therapeutics Inc's Cash amounts to 133.8m KRW.
What is Cellivery Therapeutics Inc's Cash growth rate?
Cash CAGR 5Y
166%
Over the last year, the Cash growth was -70%. The average annual Cash growth rates for Cellivery Therapeutics Inc have been 480% over the past three years , 166% over the past five years .
